DeepMed Research

UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1

Completed

Conditions: Male Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: trastuzumab

First Posted Date: 2006-05-31

Last Posted Date: 2017-07-26

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT00331552

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Pilot Community Clinical Study of Hypothermia in Cardiac Arrest

Phase 1

Completed

Conditions: Cardiac Arrest

Interventions: Drug: Up to 2 liter infusion of cold 4 degree C normal saline

First Posted Date: 2006-05-24

Last Posted Date: 2017-04-17

Lead Sponsor: University of Washington

Target Recruit Count: 125

Registration Number: NCT00329563

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

Phase 3

Completed

Conditions: Osteomyelitis
Methicillin-resistant Staphylococcus Aureus

Interventions: Drug: trimethoprim-sulfamethoxazole
Drug: vancomycin

First Posted Date: 2006-05-11

Last Posted Date: 2023-04-11

Lead Sponsor: University of Washington

Target Recruit Count: 2

Registration Number: NCT00324922

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Hypertonic Resuscitation Following Traumatic Injury

Phase 3

Terminated

Conditions: Shock, Traumatic

Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)
Drug: 7.5% hypertonic saline (HS)
Drug: 0.9% normal saline

First Posted Date: 2006-04-19

Last Posted Date: 2011-03-01

Lead Sponsor: University of Washington

Target Recruit Count: 895

Registration Number: NCT00316017

Locations: 🇺🇸
Iowa Resuscitation Network, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
🇨🇦
University of Ottawa/University of British Columbia Collaborative RCC, Ottawa Health Research Institute, Ottawa, Ontario, Canada
🇺🇸
Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University, Portland, Oregon, United States

and more 7 locations

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

Phase 3

Terminated

Conditions: Brain Injuries, Traumatic

Interventions: Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
Drug: 7.5% Hypertonic Saline (HS)
Drug: 0.9% Normal Saline (NS)

First Posted Date: 2006-04-19

Last Posted Date: 2011-05-19

Lead Sponsor: University of Washington

Target Recruit Count: 1331

Registration Number: NCT00316004

Locations: 🇺🇸
UCSD-San Diego Resuscitation Research Center, San Diego, California, United States
🇺🇸
Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇨🇦
Toronto Regional Resuscitation Research Out-of-Hospital Network, University of Toronto, Toronto, Ontario, Canada

and more 9 locations

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Phase 2

Completed

Conditions: Urinary Tract Infection

Interventions: Drug: Placebo
Drug: Lactin-V

First Posted Date: 2006-03-21

Last Posted Date: 2023-04-14

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT00305227

Locations: 🇺🇸
Hall Health Primary Care Center, University of Washington, Seattle, Washington, United States

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

Phase 2

Completed

Conditions: Cancer
Prostate Neoplasms

Interventions: Drug: goserelin with dutasteride
Drug: goserelin with bicalutamide and dutasteride
Drug: goserelin with bicalutamide and dutasteride and ketoconazole

First Posted Date: 2006-03-01

Last Posted Date: 2018-08-09

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT00298155

Locations: 🇺🇸
Veterans' Administration Puget Sound Health Care System (VAPSHCS), Seattle, Washington, United States
🇺🇸
University of Washington, Seattle, Washington, United States

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Exisulind
Drug: luteinizing hormone-releasing hormone (LHRH) agonist
Drug: Antiandrogen

First Posted Date: 2006-01-30

Last Posted Date: 2018-08-07

Lead Sponsor: University of Washington

Target Recruit Count: 32

Registration Number: NCT00283803

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: IL2

First Posted Date: 2006-01-30

Last Posted Date: 2007-11-29

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT00283829

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-01-13

Last Posted Date: 2019-02-27

Lead Sponsor: University of Washington

Target Recruit Count: 12

Registration Number: NCT00276770

Locations: 🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy